SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Entrance to the Vertex's headquarters building in Boston, Massachusetts
Pain
Vertex Nabs Priority Review for Non-Opioid Pain Drug, Awaits January 2025 Decision
The FDA will have six months to review Vertex Pharmaceuticals’ suzetrigine, potentially the first new class of drugs for acute pain in more than 20 years, according to the company.
July 31, 2024
 · 
2 min read
 · 
Tristan Manalac
Incyte's logo on its building in Delaware
Pipeline
Incyte Trims Early-Stage Pipeline Amid Strategic Shift in R&D
Incyte announced Tuesday it is realigning its research and development priorities to focus on dermatology and inflammatory assets obtained from the $750 million acquisition of Escient Pharmaceuticals.
July 31, 2024
 · 
2 min read
 · 
Tristan Manalac
Novartis' office building in Marburg, Germany
Patents
FDA Denies Novartis’ Petition to Block Entresto Generics
In addition to facing generic competition, Entresto is among the initial 10 drugs selected for the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, with the maximum fair prices to be published by Sept. 1.
July 31, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcasts
Q2 Earnings Bonanza, M&A Accelerates and Alzheimer’s Data
Second-quarter earnings season continues with Big Pharma beating Wall Street expectations, the author of an encrypted email sent to BioSpace has a proposal for Moderna and Merck, Roche and Viking seek quicker entry to the obesity market, and AAIC is in full swing.
July 31, 2024
 · 
1 min read
 · 
Greg Slabodkin
Sangamo's headquarters in Silicon Valley
Drug Development
Despite Late-Stage Hemophilia Win, Sangamo Remains in Do-or-Die Situation
Sangamo and Pfizer’s hemophilia A gene therapy candidate scored a Phase III victory last week. However, with the genomic medicine company soon to run out of cash, Sangamo’s short-term prospects look bleak but not unsalvageable, analysts say.
July 31, 2024
 · 
3 min read
 · 
Tyler Patchen
Illustration with one open hand under a question mark and another under a light bulb
Career Pathing
From Eli Lilly to Entrepreneur: A Journey to Independent Consulting
After more than 20 years at Eli Lilly, Leslie Sam moved into independent consulting. To prepare for the transition, she focused on becoming technically deep and earning industry recognition.
July 31, 2024
 · 
4 min read
 · 
Angela Gabriel
Dragon and eagle with money
Policy
BIOSECURE Act Could Signal a Seismic Shift for Biopharma in US and China
The BIOSECURE Act’s prohibition on doing business with China-based companies may have implications for biotech and biopharma markets on both sides of the Pacific.
July 31, 2024
 · 
8 min read
 · 
Sanjukta Mondal
illustration of a circular RNA molecule and IV bags
Opinion
Circular RNA Will Soon Replace mRNA in Biopharma
The advantages of using circular RNAs—including increased durability, enhanced protein expression and substantially lower manufacturing costs compared to linear mRNAs—have driven a spate of investment in this technology.
July 31, 2024
 · 
5 min read
 · 
Erik Digman Wiklund
Pictured: Photo illustration of hundred dollar bill and graph
Earnings
Pfizer, Merck Beat Wall Street Expectations Amid Strong Biopharma Q2 Earnings Season
Second-quarter revenues were better than analysts expected as Merck reported 16% growth for its blockbuster cancer treatment Keytruda, while Pfizer benefited from its ongoing cost-cutting efforts and sales of its COVID-19 antiviral Paxlovid.
July 30, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS